Compare NEXA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | ADMA |
|---|---|---|
| Founded | 1956 | 2004 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2017 | 2012 |
| Metric | NEXA | ADMA |
|---|---|---|
| Price | $14.37 | $8.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $10.40 | ★ $25.67 |
| AVG Volume (30 Days) | 740.7K | ★ 3.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $8.69 | $27.46 |
| Revenue Next Year | N/A | $22.11 |
| P/E Ratio | ★ N/A | $47.26 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $4.62 | $7.21 |
| 52 Week High | $16.89 | $20.46 |
| Indicator | NEXA | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 52.75 |
| Support Level | $13.68 | $7.38 |
| Resistance Level | $14.94 | $8.97 |
| Average True Range (ATR) | 0.82 | 0.30 |
| MACD | 0.22 | 0.05 |
| Stochastic Oscillator | 81.89 | 60.45 |
Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.